• LAST PRICE
    0.1110
  • TODAY'S CHANGE (%)
    Trending Down-0.0148 (-11.7694%)
  • Bid / Lots
    0.0801/ 100
  • Ask / Lots
    0.1734/ 50
  • Open / Previous Close
    0.1110 / 0.1258
  • Day Range
    Low 0.1110
    High 0.1110
  • 52 Week Range
    Low 0.0761
    High 0.2372
  • Volume
    20,000
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 10, 2024

      Show headlines and story abstract
    • 8:46AM ET on Tuesday Sep 10, 2024 by Newsfile
      Companies Mentioned: TDSGF

      Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study.

    • 8:46AM ET on Tuesday Sep 10, 2024 by Dow Jones
      Companies Mentioned: TELO

      Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study.

Peers Headlines

No documents available